ArticleCancer discovery2019

Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?

Jose M Pacheco et al.PubMed ↗Publisher ↗

No numbers read from the abstract.